BRAF and non-small cell lung carcinoma: The combination of BRAF and mitogen-activated protein kinase (MEK) inhibitors (dabrafenib and trametinib) has shown efficacy in BRAF V600E-mutant NSCLC, as demonstrated by Planchard et al. [112].